<- Go Home
Dyax Corp.
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders.
Market Cap
$5.7B
Volume
1.7M
Cash and Equivalents
$94.6M
EBITDA
-$43.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$11.8M
Profit Margin
13.57%
52 Week High
$38.56
52 Week Low
$14.06
Dividend
N/A
Price / Book Value
19.69
Price / Earnings
-91.10
Price / Tangible Book Value
19.69
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$44.3M
Return on Equity
-30.88%
Return on Assets
-9.99
Cash and Short Term Investments
$294.4M
Debt
N/A
Equity
$287.2M
Revenue
$87.1M
Unlevered FCF
$11.5M
Sector
Biotechnology
Category
N/A